As of 2:31 PM on the 8th, Seegene is trading at 144,100 KRW, up 8.92% from the previous day. The trading volume is 8,520,091 shares, which is 150.17% of the previous day's volume. Seegene is known as a developer, manufacturer, and seller of molecular diagnostic reagents.

On July 8th, Hana Financial Investment researcher Minjeong Seon reported, "In the case of the GH type virus mutation, it has been reported that the transmissibility has increased sixfold compared to the existing virus. It is expected that it will take more than three years for vaccine and therapeutic development to be completed due to this mutation. The COVID-19 pandemic is not a one-time event but a long-term event lasting more than three years. There is a need to re-rate Seegene's valuation." She set Seegene's target price at 200,000 KRW.

Over the past five days, individual investors have net sold 201,000 shares of Seegene, while foreigners and institutions have net bought 188,013 shares and 51,850 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing